Objective: N-Acetylglucosaminyltransferase V (GnT-V) is a key enzyme in the formation of branching asparagine-linked oligosaccharides and is linked to tumor invasion and metastasis in colon and breast cancers. In normal esophageal epithelium, β1,6-branched asparagine-linked oligosaccharides synthesized by GnT-V are seen in the basal cell layers but not in the superficial cell layers, and its presence has been shown in invasive esophageal cancers. However, neither GnT-V expression nor its clinical significance has been previously examined in human normal, premalignant and malignant esophageal tissues. Methods: GnT-V expression was studied by immunohistochemistry using a specific monoclonal antibody in 121 surgically resected specimens of esophageal squamous cell carcinomas (SCCs) and adjacent tissues, and was analyzed statistically in relation to various characteristics. Results: GnT-V expression was observed in none (0%) of the 19 normal epithelial tissues, 1 (2%) of the 43 hyperplastic tissues, 30 (54%) of the 56 mildly dysplastic tissues, 27 (63%) of the 43 moderately dysplastic tissues, 21 (44%) of the 48 in situ SCCs and 29 (26%) of the 110 invasive SCCs (p < 0.005). GnT-V expression was observed significantly more frequently in mildly and moderately dysplastic tissues when compared with normal epithelial and hyperplastic tissues (p < 0.005), and its frequency was decreased in in situ and invasive SCCs (p < 0.005). GnT-V expression was frequently observed in SCCs of small size and without distant metastasis or lymph node metastasis. Conclusions: Increased expression of GnT-V is associated with the early event of esophageal tumorigenesis.

Keywords:
GnT-V, Carcinogenesis, Esophageal cancer, L4-PHA, Ki-67
1.
Ando N, Ozawa S, Kitagawa Y, Shinozawa Y, Kitajima M: Improvement in the results of surgical treatment of advanced squamous esophageal carcinoma during 15 consecutive years. Ann Surg 2000;232:225–232.
2.
Adham M, Baulieux J, Mornex F, de La Roche de Bransat E, Ducerf C, Souquet JC, Gerard JP: Combined chemotherapy and radiotherapy followed by surgery in the treatment of patients with squamous cell carcinoma of the esophagus. Cancer 2000;89:946–954.
3.
Collard JM, Otte JB, Fiasse RF, Laterre PF, De Knock M, Longueville J, Glineur D, Romagnoli R, Reynaert M, Kestens PJ: Skeletonizing en bloc esophagectomy for cancer. Ann Surg 2001;234:25–32.
4.
Torres C, Turner JR, Wang HH, Richards W, Sugarbaker D, Shahsafaei A, Odze RD: Pathologic prognosis factors in Barrett’s associated adenocarcinoma: a follow-up study of 96 patients. Cancer 1999;85:520–528.
5.
Ando N, Iizuka T, Kakegawa T, Isono, K, Watanabe H, Ide H, Tanaka O, Shinoda M, Takiyama W, Arimori M, Ishida K, Tsugane S: A randomized trial of surgery with and without chemotherapy for localized squamous carcinoma of the thoracic esophagus: The Japan Clinical Oncology Group study. J Thorac Cardiovasc Surg 1997;114:205–209.
6.
Rademacher TW, Parekh RB, Dwek RA: Glycobiology. Annu Rev Biochem 1988;57:785–838.
7.
Hakomori S: Aberrant glycosylation in tumors and tumor-associated carbohydrate antigens. Adv Cancer Res 1989;52:257–331.
8.
Cummings RD, Trowbridge IS, Kornfeld S: A mouse lymphoma cell line resistant to the leukoagglutinating lectin from Phaseolus vulgaris is deficient in UDP-GlcNAc:alpha-D-mannoside beta 1,6 N-acetylglucosaminyltransferase. J Biol Chem 1982;257:13421–13427.
9.
Yamashita K, Tachibana I, Ohkura T, Kobata A: Enzymatic basis for the structure changes of asparagine-linked sugar chains of membrane glycoproteins of baby hamster kidney cells induced polyoma transformation. J Biol Chem 1985;260:3963–3969.
10.
Pierce M, Arango J: Rous sarcoma virus-transformed baby hamster kidney cells express higher levels of asparagine-linked tri- and tetraantennary glycopeptides containing [GlcNAc- beta (1,6)Man-alpha (1,6)Man] and poly-N-acetyllactosamine sequences than baby hamster kidney cells. J Biol Chem 1986;261:10772–10777.
11.
Demetriou M, Nabi IR, Coppolino M, Dedhar S, Dennis JW: Reduced contact-inhibition and substratum adhesion in epithelial cells expressing GlcNAc-transferase V. J Cell Biol 1995;130:383–392.
12.
Miyoshi E, Nishikawa A, Ihara Y, Gu J, Sugiyama T, Hayashi N, Fusamoto H, Kamada T, Taniguchi N: N-Acetylglucosaminyltransferase III and V messenger RNA levels in LEC rats during hepatocarcinogenesis. Cancer Res 1993;53:3899–3902.
13.
Seelentag WK, Li WP, Schmitz SF, Metzger U, Aeberhard P, Heitz PU, Roth J: Prognostic value of beta1,6-branched oligosaccharides in human colorectal carcinoma. Cancer Res 1998;58:5559–5564.
14.
Granovsky M, Fata J, Pawling J, Muller WJ, Khokha R, Dennis JW: Suppression of tumor growth and metastasis in Mgat5-deficient mice. Nat Med 2000;6:306–312.
15.
Dennis JW, Laferte S, Waghorne C, Breitman ML, Kerbel RS: Beta 1–6 branching of Asn-linked oligosaccharides is directly associated with metastasis. Science 1987;236:582–585.
16.
Fernandes B, Sagman U, Auger M, Demetrio M, Dennis JW: Beta 1–6 branched oligosaccharides as a marker of tumor progression in human breast and colon neoplasia. Cancer Res 1991;51:718–723.
17.
Murata K, Miyoshi E, Kameyama M, Ishikawa O, Kabuto T, Sasaki Y, Hiratsuka M, Ohigashi H, Ishiguro S, Ito S, Honda H, Takemura F, Taniguchi N, Imaoka S: Expression of N-acetylglucosaminyltransferase V in colorectal cancer correlates with metastasis and poor prognosis. Clin Cancer Res 2000;6:1772–1777.
18.
Ito Y, Miyoshi E, Sakon M, Takeda T, Noda K, Tsujimoto M, Ito S, Honda H, Takemura F, Wakasa K, Monden M, Matsuura N, Taniguchi N: Elevated expression of UDP-N-acetylglucosamine: alphamannoside beta1,6 N-acetylglucosaminyltransferase is an early event in hepatocarcinogenesis. Int J Cancer 2001;91:631–637.
19.
Li WP, Roth J: Expression of beta 1,6 branched asparagine-linked oligosaccharides in non-mitotic and non-migratory cells of normal human and rat tissues. Int J Cancer 1997;71:483–490.
20.
Takano R, Nose M, Nishihira T, Kyogoku M: Increase of beta 1-6-branched oligosaccharides in human esophageal carcinomas invasive against surrounding tissue in vivo and in vitro. Am J Pathol 1990;137:1007–1011.
21.
International Union Against Cancer: TNM Classification of Malignant Tumours, ed 6. New York, Wiley-Liss, 2002, pp 60–64.
22.
Cummings RD, Kornfeld S: Characterization of the structural determinants required for the high affinity interaction of asparagine-linked oligosaccharides with immobilized Phaseolus vulgaris leukoagglutinating and erythroagglutinating lectins. J Biol Chem 1982;257:11230–11234.
23.
Miyoshi E, Ihara Y, Hayashi N, Fusamoto H, Kamada T, Taniguchi N: Transfection of N-acetylglucosaminyltransferase III gene suppresses expression of hepatitis B virus in a human hepatoma cell line, HB611. J Biol Chem 1995;270:28311–28315.
24.
Gerdes J, Schwab U, Lemke H, Stein H: Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 1983;31:13–20.
25.
Ishikuro A, Dosaka-Akita H, Kato M, Fujino M, Isobe H, Miyamoto H, Inoue K, Kawakami Y: Ki-67 labeling indices in non-small cell lung cancer: comparison between image cytometry and flow cytometry. Cytometry 1997;30:186–191.
26.
Dosaka-Akita H, Miyoshi E, Suzuki O, Itoh T, Katoh H, Taniguchi N: Expression of N-acetylglucosaminyltransferase v is associated with prognosis and histology in non-small cell lung cancers. Clin Cancer Res 2004;10:1773–1779.
27.
Guo HB, Lee I, Kamar M, Akiyama SK, Pierce M: Aberrant N-glycosylation of beta1 integrin causes reduced alpha5beta1 integrin clustering and stimulates cell migration. Cancer Res 2002;62:6837–6845.
28.
Ihara S, Miyoshi E, Ko JH, Murata K, Nakahara S, Honke K, Dickson RB, Lin CY, Taniguchi N: Prometastatic effect of N-acetylglucosaminyltransferase V is due to modification and stabilization of active matriptase by adding beta 1-6 GlcNAc branching. J Biol Chem 2002;277:16960–16967.
29.
Saitoh O, Wang WC, Lotan R, Fukuda M: Differential glycosylation and cell surface expression of lysosomal membrane glycoproteins in sublines of a human colon cancer exhibiting distinct metastatic potentials. J Biol Chem 1992;267:5700–5711.
30.
Inamori K, Endo T, Ide Y, Fujii S, Gu J, Honke K, Taniguchi N: Molecular cloning and characterization of human GnT-IX, a novel beta1,6-N-acetylglucosaminyltransferase that is specifically expressed in the brain. J Biol Chem 2003;278:43102–43109.
31.
Inamori K, Endo T, Gu J, Matsuo I, Ito Y, Fujii S, Iwasaki H, Narimatsu H, Miyoshi E, Honke K, Taniguchi N: N-Acetylglucosaminyltransferase IX acts on the GlcNAc beta 1,2-Man alpha 1-Ser/Thr moiety, forming a 2,6-branched structure in brain O-mannosyl glycan. J Biol Chem 2004;279:2337–2340.
32.
Kaneko M, Alvarez-Manilla G, Kamar M, Lee I, Lee JK, Troupe K, Zhang W, Osawa M, Pierce M: A novel beta(1,6)-N-acetylglucosaminyltransferase V (GnT-VB)(1). FEBS Lett 2003;554:515–519.
33.
Sasai K, Ikeda Y, Fujii T, Tsuda T, Taniguchi N: UDP-GlcNAc concentration is an important factor in the biosynthesis of beta1,6-branched oligosaccharides: regulation based on the kinetic properties of N-acetylglucosaminyltransferase V. Glycobiology 2002;12:119–127.
34.
Sasai K, Ikeda Y, Eguchi H, Tsuda T, Honke K, Taniguchi N: The action of N-acetylglucosaminyltransferase-V is prevented by the bisecting GlcNAc residue at the catalytic step. FEBS Lett 2002;522:151–155.
35.
Sasaki K, Murakami T, Kawasaki M: The cell cycle associated change of the Ki-67 reactive nuclear antigen expression. J Cell Physiol 1987;133:579–584.
36.
Lam KY, Law SY, So MK, Fok M, Ma LT, Wong J: Prognostic implication of proliferative markers MIB-1 and PC10 in esophageal squamous cell carcinoma. Cancer 1996;77:7–13.
37.
Kawamura T, Goseki N, Koike M, Takizawa T, Endo M: Acceleration of proliferative activity of esophageal squamous cell carcinoma with invasion beyond the mucosa: immunohistochemical analysis of Ki-67 and p53 antigen in relation to histopathologic findings. Cancer 1996;77:843–849.
© 2005 S. Karger AG, Basel
2005
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.